Variation in the definitions of bleeding in clinical trials of patients with acute coronary syndromes and undergoing percutaneous coronary interventions and its impact on the apparent safety of antithrombotic drugs

被引:96
作者
Steinhubl, Steven R.
Kastrati, Adnan
Berger, Peter B.
机构
[1] Univ Kentucky, Coll Med, Gill Heart Inst, Lexington, KY 40536 USA
[2] Tech Univ Munich, Deutsch Herzzentrum, D-8000 Munich, Germany
[3] Geisinger Med Ctr, Danville, PA 17822 USA
关键词
D O I
10.1016/j.ahj.2007.04.009
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background This review compares and contrasts the various criteria used to characterize bleeding (particularly major bleeding) during recent studies of antithrombotic therapies in acute coronary syndromes (ACSs) and/or percutaneous coronary intervention (PCI). Methods This review includes an analysis of recent large randomized clinical trials (published between January 2000 and September 2006; n > 3000 patients) evaluating antithrombotic drugs in patients with ACS or patients undergoing PCI who were identified using Medline searches. Results Bleeding has been shown to correlate with patient mortality and major cardiovascular events. Different definitions of bleeding, other than Thrombolysis In Myocardial Infarction or Global Utilization of Streptokinase and PA for Occluded coronary arteries bleeding criteria, were used in 9 of the 13 randomized trials that were identified and enrolled over 178,000 patients in total. These definitions overlapped to a degree but differed substantially. Bleeding rates according to several bleeding criteria within one trial illustrate that different bleeding definitions can lead to markedly different conclusions about the safety of an antithrombotic regimen. The shift toward identifying therapies that specifically attempt to reduce bleeding while maintaining efficacy at reducing ischernic complications increases the need of standardized bleeding definitions. Conclusions A task force should be initiated to formulate an internationally accepted, meaningful, and standardized approach for reporting bleeding events. A fixed definition may not work for all disease states throughout ACS and PCI. Rather, a predefined scale of bleeding can be proposed, which moves from a more liberal definition of bleeding for elective PCI to a more conservative definition in other settings such as rescue angioplasty.
引用
收藏
页码:3 / 11
页数:9
相关论文
共 35 条
[21]   Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes [J].
Rao, SV ;
O'Grady, K ;
Pieper, KS ;
Granger, CB ;
Newby, LK ;
Van de Werf, F ;
Mahaffey, KW ;
Califf, RM ;
Harrington, RA .
AMERICAN JOURNAL OF CARDIOLOGY, 2005, 96 (09) :1200-1206
[22]   Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes [J].
Rao, SV ;
Jollis, JG ;
Harrington, RA ;
Granger, CB ;
Newby, LK ;
Armstrong, PW ;
Moliterno, DJ ;
Lindblad, L ;
Pieper, K ;
Topol, EJ ;
Stamler, JS ;
Califf, RM .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (13) :1555-1562
[23]   Association of hemoglobin levels with clinical outcomes in acute coronary syndromes [J].
Sabatine, MS ;
Morrow, DA ;
Giugliano, RP ;
Burton, PBJ ;
Murphy, SA ;
McCabe, CH ;
Gibson, CM ;
Braunwald, E .
CIRCULATION, 2005, 111 (16) :2042-2049
[24]   A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents [J].
Schomig, A ;
Neumann, FJ ;
Kastrati, A ;
Schuhlen, H ;
Blasini, R ;
Hadamitzky, M ;
Walter, H ;
ZitzmannRoth, EM ;
Richardt, G ;
Alt, E ;
Schmitt, C ;
Ulm, K .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (17) :1084-1089
[25]   Assessment of bleeding events in clinical trials - Proposal of a new classification [J].
Serebrulany, Victor L. ;
Atar, Dan .
AMERICAN JOURNAL OF CARDIOLOGY, 2007, 99 (02) :288-290
[26]  
Simoons ML, 2001, LANCET, V357, P1915
[27]   Acute catheterization and urgent intervention triage strategY (ACUITY) trial: Study design and rationale [J].
Stone, GW ;
Bertrand, M ;
Colombo, A ;
Dangas, G ;
Farkouh, ME ;
Feit, F ;
Lansky, AJ ;
Lincoff, AM ;
Mehran, R ;
Moses, JW ;
Ohman, M ;
White, HD .
AMERICAN HEART JOURNAL, 2004, 148 (05) :764-775
[28]   AN INTERNATIONAL RANDOMIZED TRIAL COMPARING 4 THROMBOLYTIC STRATEGIES FOR ACUTE MYOCARDIAL-INFARCTION [J].
TOPOL, E ;
CALIFF, R ;
VANDEWERF, F ;
ARMSTRONG, PW ;
AYLWARD, P ;
BARBASH, G ;
BATES, E ;
BETRIU, A ;
BOISSEL, JP ;
CHESEBRO, J ;
COL, J ;
DEBONO, D ;
GORE, J ;
GUERCI, A ;
HAMPTON, J ;
HIRSH, J ;
HOLMES, D ;
HORGAN, J ;
KLEIMAN, N ;
MARDER, V ;
MORRIS, D ;
OHMAN, M ;
PFISTERER, M ;
ROSS, A ;
RUTSCH, W ;
SADOWSKI, Z ;
SIMOONS, M ;
VAHANIAN, A ;
WEAVER, WD ;
WHITE, H ;
WILCOX, R .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (10) :673-682
[29]   Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. [J].
Topol, EJ ;
Moliterno, DJ ;
Herrmann, HC ;
Powers, ER ;
Grines, CL ;
Cohen, DJ ;
Cohen, EA ;
Bertrand, M ;
Neumann, FJ ;
Stone, GW ;
DiBattiste, PM ;
Demopoulos, L .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (25) :1888-1894
[30]  
Van de Werf F, 2001, LANCET, V358, P605